Infectious Disease Diagnosis & Treatment Market Research Report-  Asia Pacific Forecast to 2032

Asia Pacific Infectious Disease Diagnosis & Treatment Market Research Report, By Applications (AIDS, Tuberculosis (TB), Hepatitis, HPV, And Others), By Treatment (Antibiotics, Antivirals, Antifungals, Anti-Parasitic, Alternative Medicine And Others), By Diagnostic Techniques (Immunoassays, PCR, Cell Cultures And Other), By End Users (Hospitals, Clinics, Reference Labs And Others)- Forecast Till 2032

ID: MRFR/MED/0814-HCR | 80 Pages | Author: Kinjoll Dey | March 2024         

Asia Pacific Infectious Disease Diagnosis & Treatment Market Overview


The Infectious Disease Diagnosis & Treatment market is anticipated to reach USD 3.1 Billion by 2032 at a CAGR 2.9% during the forecast period 2023-2032.


The infectious disease diagnosis & treatment market is anticipated to grow substantially in the years to come. The infectious illness diagnosis and treatment market value was estimated at around USD 179.58 Billion in the year 2018. infectious disease diagnosis & treatment market is expected to grow at a CAGR (Compound Annual Growth Rate) of about 7.84% in the coming years.


Bacteria, viruses, fungi, and parasites are all responsible for infectious disorders. These illnesses can be spread by insects, animals, contaminated food or drink, or exposure to an infected environment. The market is predicted to escalate due to the rising incidence of infectious illnesses and increased awareness of these diseases. According to a World Health Organization (WHO) report, almost 50,000 people die every day due to infectious diseases.


Asia Pacific Infectious Disease Diagnosis & Treatment Market Overview


Covid-19 Analysis


With the rise of the Covid-19 impact, many large-scale businesses and industries suffered, except healthcare and life support products. The lockdown and physical distancing protocols have affected millions of small and big business institutions alike. The infectious illnesses diagnosis & treatment market saw a slight downfall due to the lockdown and physical distancing.


However, the key companies have adopted measures to expand the distribution of infectious illnesses treatment and diagnosis equipment across the globe. Moreover, people are growing aware of infectious diseases, and the price of pharmaceutical products is increasing. Hence, these factors are expected to boost the infectious disease diagnosis & treatment market value in the years to come.


Asia Pacific Infectious Disease Diagnosis & Treatment Market Trends


Drivers


Infectious illness prevalence in both established and emerging nations would boost the infectious disease diagnosis & treatment market growth. The rising number of prescriptions for infectious illness diagnostic tests is due to diagnosing and managing such disorders. Over the forecast period, these factors, together with the increasing tendency toward preventative care, are projected to increase demand for infectious disease diagnosis & treatment market.


Opportunities 


Due to multiple major and minor significant players, the infectious illnesses treatment & diagnosis market seems fragmented. These market participants attempt to acquire a competitive edge through strategic initiatives such as partnership, acquisition, expansion, cooperation, and product and technology launches. Significant efforts are being made in R&D to produce unique diagnoses & treatment options.


Restraints 


A few factors may inhibit the growth of the infectious disease diagnosis & treatment market share. The development of the infectious illness treatment market is likely to be hampered by stringent government restrictions and a lack of information about treatment choices in developing nations. Inadequate reimbursement is a key stumbling block to the infectious disease diagnostics market's development.


Challenges 


There are various concerns with the market that may challenge the key players of the infectious disease diagnosis & treatment market. This includes the cost of the diagnosis and treatment solutions. High treatment and maintenance costs for infectious diseases and a lack of infrastructure in medium and low-income nations may limit the expansion of the market. Most diagnostic companies have a significant challenge in commercializing their tests, convincing their health insurance to pay for them.


Cumulative Growth Analysis


The infectious disease diagnosis & treatment market is anticipated to grow substantially in the years to come. The infectious illness market value was estimated at around USD 179.58 Billion in 2018 and is expected to grow at a CAGR of about 7.84% in the coming years.


Value Chain Analysis


During the infectious disease diagnosis & treatment market forecast, demand for diagnostics is likely to be driven by the expanding trend of preventive medicine. To strengthen Covid-19 preventive and control efforts, large-scale population-based testing is necessary. Infectious illness diagnostics performs these tests. Hence, it is likely to have a favorable influence on infectious disease diagnosis & treatment market.


Developing economies such as India, South Korea, Brazil, and Mexico will likely provide significant infectious illness diagnostics market participants with new growth prospects. The high illness incidence, big patient population, better healthcare infrastructure, increasing disposable money, and growing medical tourism in these nations contribute to this. Aside from the aforementioned characteristics, the Asia Pacific region has grown as a flexible and business-friendly center due to less strict rules and data requirements.


Asia Pacific Infectious Disease Diagnosis & Treatment Market Segmentation


The global infectious disease diagnosis & treatment market is classified into many segments such as disease types, treatment, and end-user. Listed below are the infectious illness treatment & diagnosis market segments:


Disease Type Outlook



  • Bacterial diseases

  • Viral diseases

  • Fungal diseases

  • Parasitic diseases

  • Others


Treatment Outlook



  • Antibiotics

  • Antivirals

  • Antifungals

  • Anti-parasitic

  • Others


End-user Outlook



  • Hospitals & clinics

  • Ambulatory Care Centers

  • Others


Regional Analysis


The regional division of the infectious disease diagnosis & treatment market analysis comprises North America, Europe, Asia Pacific, and the rest of the world. The Americas are expected to dominate the infectious disease treatment market due to a rising patient population suffering from different kinds of infectious illnesses and a growing number of government efforts to prevent contagious diseases in the area.


Due to rising awareness and an increasing patient population suffering from severe infectious diseases, Europe is expected to hold the second-largest position in the infectious disease diagnosis & treatment market. According to the WHO, 14 million people in Europe are infected with hepatitis C as of 2018. Due to the huge patient population suffering from bacterial infectious illnesses and the increasing number of activities conducted by governments and private organizations to raise awareness about infectious diseases, Asia-Pacific is predicted to be the fastest-growing regional market.


According to a May 2018 study released by the National Center for Biotechnology Information (NCBI), meningitis and pneumonia account for roughly 22% of mortality among children under five in India. Because of the expanding patient population suffering from various infectious illnesses, the infectious disease diagnosis & treatment market in the Middle East and Africa is predicted to rise slowly.


Competitive Landscape 


The infectious disease diagnosis & treatment industry is dominated by a few companies that play a vital role in the market growth. These infectious illnesses diagnosis and treatment provider companies are called key companies of the market. They contribute to the largest share of the infectious disease diagnosis & treatment market profit.

The companies account for the market profits by adopting various infectious disease diagnosis & treatment market trends such as joint ventures, product launches, company expansions, and procurements. They provide innovative solutions for patients suffering from infectious illnesses.


Key Players


Below are the key companies that offer infectious illness diagnosis and treatment solutions in the global infectious disease diagnosis & treatment market, along with the location of their headquarters:



  • Pfizer Inc. (US)

  • Bristol-Myers Squibb Company (US)

  • Janssen Global Services LLC (US)

  • Eli Lilly and Company (US)

  • Ortho Clinical Diagnostics (US)

  • Merck & Co. Inc. (US)

  • AbbVie Inc. (US)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Novartis AG (Switzerland)

  • Aurobindo Pharma (India)

  • Bayer AG (Germany)

  • Reddy's Laboratories (India)

  • Sanofi (France)

  • Cipla Inc. (India)

  • Seegene Inc. (South Korea)

  • ABACUS Diagnostica Oy (Finland)

  • GlaxoSmithKline PLC (UK)

  • Alkem Labs (India)

  • Astellas Pharma Inc. (Japan)


Recent Development:

November 2023


Abbott Laboratories announces the launch of its new Panbio™ COVID-19 Ag Rapid Test Nasal, a rapid antigen test for COVID-19 that can be performed in just 15 minutes using a nasal swab. The test is designed for professional use and is intended to be used as an aid in the diagnosis of COVID-19 infection.

Becton, Dickinson and Company (BD) announces the launch of its new BD MAX™ System for the detection of Omicron subvariants. The BD MAX™ System is a molecular diagnostic platform that can be used to detect a wide range of infectious pathogens, including viruses, bacteria, and fungi.

Roche Diagnostics announces the launch of its new cobas® Liat® System MRSA Test, a rapid molecular diagnostic test for the detection of methicillin-resistant Staphylococcus aureus (MRSA). The cobas® Liat® System MRSA Test is designed to be used in point-of-care settings and can provide results in less than 60 minutes.

October 2023

Thermo Fisher Scientific announces the launch of its new Applied Biosystems™ TaqMan™ SARS-CoV-2 Mutation Assays, which are designed to detect and differentiate between the most common SARS-CoV-2 variants of concern. The Applied Biosystems™ TaqMan™ SARS-CoV-2 Mutation Assays can be used on a variety of Thermo Fisher Scientific real-time PCR instruments.

Qiagen announces the launch of its new QIAprep® Viral RNA Mini Kit Plus, a high-performance kit for the extraction of viral RNA from a variety of sample types, including nasopharyngeal swabs, saliva, and wastewater. The QIAprep® Viral RNA Mini Kit Plus is designed to be used with a variety of molecular diagnostic platforms, including the Qiagen QIAcuity™ and QIAcube™ instruments.

Report Scope:

Report Attribute/Metric Details
Market Size 2032 USD 3.1 billion
Compound Annual Growth Rate (CAGR)  2.9% (2023-2032)
Base Year 2023
Market Forecast Period 2023-2032
Historical Data 2018 - 2021
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered disease types, treatment, and end-user
Geographies Covered North America, Europe, Asia Pacific, and the rest of the world
Countries Covered China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific
Key Companies Profiled Pfizer Inc. (US)Bristol-Myers Squibb Company (US)Janssen Global Services LLC (US)Eli Lilly and Company (US)Ortho Clinical Diagnostics (US)Merck & Co. Inc. (US)AbbVie Inc. (US)
Key Market Opportunities Partnership, acquisition, expansion, cooperation, and product and technology launches
Key Market Dynamics Technological advancement Macro economical and governing factors




Frequently Asked Questions (FAQ) :

The Americas are expected to dominate the infectious disease treatment market due to a rising patient population suffering from different kinds of infectious illnesses and a growing number of government efforts to prevent the spread of infectious diseases in the area.

The major key players in the infectious illnesses diagnosis & treatment market include Pfizer Inc. (US), Bristol-Myers Squibb Company (US), Janssen Global Services LLC (US), Eli Lilly and Company (US), Merck & Co. Inc. (US), AbbVie Inc. (US), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Aurobindo Pharma (India), Seegene Inc. (South Korea), ABACUS Diagnostica Oy (Finland), Bayer AG (Germany), Dr. Reddy's Laboratories (India), Sanofi (France), Cipla Inc. (India), GlaxoSmithKline PLC (UK), Alkem Labs (India), and Astellas Pharma Inc. (Japan).

The forecast period for the infectious disease diagnosis & treatment market research report is 2023 to 2032.

The global infectious illnesses diagnosis & treatment industry is anticipated to grow at a CAGR of 2.9%.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid